328 related articles for article (PubMed ID: 28820157)
1. Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects.
Rishi P; Rishi E; Sharma M; Maitray A; Bhende M; Gopal L; Sharma T; Ratra D; Sen P; Bhende P; Rao C; Susvar P
Indian J Ophthalmol; 2017 Aug; 65(8):712-718. PubMed ID: 28820157
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
3. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy.
Hirami Y; Tsujikawa A; Otani A; Yodoi Y; Aikawa H; Mandai M; Yoshimura N
Retina; 2007 Mar; 27(3):335-41. PubMed ID: 17460589
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
5. Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.
Sen P; Bhende M; Sachidanandam R; Bansal N; Sharma T
Indian J Ophthalmol; 2016 Dec; 64(12):908-913. PubMed ID: 28112132
[TBL] [Abstract][Full Text] [Related]
6. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Shirakata Y; Fujiwara A
Am J Ophthalmol; 2013 Jan; 155(1):96-102.e1. PubMed ID: 22995028
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
8. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Kang HM; Kim YM; Koh HJ
Am J Ophthalmol; 2013 Mar; 155(3):438-447.e1. PubMed ID: 23218705
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
[TBL] [Abstract][Full Text] [Related]
10. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
11. Peripheral polypoidal choroidal vasculopathy as a cause of peripheral exudative hemorrhagic chorioretinopathy: a report of 10 eyes.
Goldman DR; Freund KB; McCannel CA; Sarraf D
Retina; 2013 Jan; 33(1):48-55. PubMed ID: 22836900
[TBL] [Abstract][Full Text] [Related]
12. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
13. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
15. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
17. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
18. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
